Beta thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains in hemoglobin, leading to ineffective red blood cell production and anemia. The severity of symptoms can vary from mild to severe, depending on the specific genetic mutations involved. Treatment may involve blood transfusions, iron chelation therapy to manage iron overload, and in some cases, bone marrow transplantation or gene therapy to address the underlying genetic defect.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
It is crucial to raise awareness about beta thalassemia to cultivate understanding and provide support for individuals impacted by this condition. At Leapcure, we're dedicated to empowering patients and advocates by providing resources, including information, personal testimonials, and connections to support groups tailored to support individuals with beta thalassemia.
Read more...
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...